Drug induced parkinsonism: A common cause of parkinsonism in older people

Postgraduate Medical Journal

Volumn 85, Issue 1004, 2009, Pages 322-326

  Thanvi, B ^a   Treadwell, S ^b  

^a SOUTH WARWICKSHIRE NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; AMLODIPINE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTIVIRUS AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORPROMAZINE; CINNARIZINE; CLOZAPINE; DILTIAZEM; FLUNARIZINE; LEVOTHYROXINE; LITHIUM; MEDROXYPROGESTERONE; METOCLOPRAMIDE; NEUROLEPTIC AGENT; NIFEDIPINE; OLANZAPINE; PROCHLORPERAZINE; QUETIAPINE; RISPERIDONE; TAMOXIFEN; TETRABENAZINE; THALIDOMIDE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

AKATHISIA; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; DYSTONIA; EXTRAPYRAMIDAL SYNDROME; HEART DISEASE; HUMAN; MOTOR DYSFUNCTION; PARKINSONISM; PSYCHOSIS; REVIEW; RIGIDITY; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT RESPONSE; TREMOR;

AGED; ANTICONVULSANTS; ANTIEMETICS; ANTIPSYCHOTIC AGENTS; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; MALE; PARKINSON DISEASE, SECONDARY;

EID: 67649700451     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2008.073312     Document Type: Review

References (41)

1. Wenning GK, Kiechl S, Seppi K, et al. Prevalence of movement disorders in men and women aged 50-89 years (Bruneck Study cohort): a population-based study. Lancet Neurol 2005;4:815-820 (Pubitemid 41619436)
2. Barbosa MT, Caramelli P, Maia DP, et al. Parkinsonism and Parkinson's disease in the elderly: a community-based survey in Brazil (the Bambuí study). Mov Disord 2006;21:800-808 (Pubitemid 44028300)
3. Kuzuhara S. Drug-induced parkinsonism. Nippon Rinsho 1997;55:112-117
4. Benito-Leon J, Bermejo-Pareja F, Rodríguez J, et al. Neurological Disorders in Central Spain (NEDICES) Study Group. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord 2003;18:267-274
5. Gershanik OS. Drug-induced parkinsonism in the aged. Recognition and prevention. Drugs Aging 1994;5:127-132
6. Esper CD, Factor SA. Failure of recognition of drug-induced parkinsonism in the elderly. Mov Disord 2008;23:401-404
7. Avorn J, Bohn RL, Mogun H, et al. Neuroleptic drug exposure and treatment of parkinsonism in the elderly: a case-control study. Am J Med 1995;99:48-54.
8. Lera G, Zirulnik J. Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism. Mov Disord 1999;14:128-131 (Pubitemid 29224687)
9. Janno S, Holi M, Tuisku K, et al. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004;161:160-163 (Pubitemid 38419323)
10. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45 (Pubitemid 34151336)
11. Cortese L, Caligiuri MP, Williams R, et al. Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia. J Clin Psychopharmacol 2008;28:69-73.
12. Merims D, Balas M, Peretz C, et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006;29:331-337 (Pubitemid 44729944)
13. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004;27:4-5. (Pubitemid 38280379)
14. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47:27-38. (Pubitemid 34302921)
15. Fumagalli F, Frasca A, Racagni G, et al. Dynamic regulation of glutamatergic postsynaptic activity in rat prefrontal cortex by repeated administration of antipsychotic drugs. Mol Pharmacol 2008;73:1484-1490 (Pubitemid 351574838)
16. Bateman DN, Darling WM, Boys R, et al. Extrapyramidal reactions to metoclopramide and prochlorperazine. Q J Med 1989;71:307-311 (Pubitemid 19142556)
17. Ganzini L, Casey DE, Hoffman WF, et al. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993;153:1469-1475 (Pubitemid 23191054)
18. Fabiani G, Pastro PC, Froehner C. Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine. Arq Neuropsiquiatr 2004;62:784-788 (Pubitemid 39366021)
19. Brucke T, Wober C, Podreka I, et al. D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. Journal of Cerebral Flow and Metabolism 1995;15:513-518
20. Giménez-Roldán S, Mateo D. Cinnarizine-induced parkinsonism. Clin Neuropharmacol 1991;14:156-164
21. Sempere AP, Duarte J, Cabezas C, et al. Parkinsonism induced by amlodipine. Mov Disord 1995;10:115-116
22. Shepard PD, Stump D. Nifedipine blocks apamin-induced bursting activity in nigral dopamine-containing neurons. Brain Res 1999;817:104-109 (Pubitemid 29225350)
23. Jamora D, Lim SH, Pan A, et al. Valproate-induced parkinsonism in epilepsy patients. Mov Disord 2007;22:130-133 (Pubitemid 46382687)
24. Zadikoff C, Munhoz RP, Asante AN, et al. Movement disorders in patients taking anticonvulsants. J Neurol Neurosurg Psychiatry 2007;78:147-151 (Pubitemid 46220211)
25. Dallocchio C, Mazzarello P. A case of parkinsonism due to lithium intoxication: treatment with pramipexole. J Clin Neurosci 2002;9:310-311 (Pubitemid 34885573)
26. Kelly KM, Gross RA, Macdonald RL. Valproic acid selectively reduces the low-threshold (T) calcium current in rat nodose neurons. Neurosci Lett 1990;116:233-238 (Pubitemid 20237166)
27. Llau ME, Nguyen L, Senard JM, et al. Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance. Rev Neurol (Paris) 1994;150:757-762
28. Caligiuri MR, Jeste DV, Lacro JP. Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations. Drugs Aging 2000;17:363-384
29. Alvarez MV, Evidente VG. Understanding drug-induced parkinsonism: separating pearls from oysters. Neurology 2008;70:e32-4
30. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988;51:850-854 (Pubitemid 18171731)
31. Tolosa E, Coelho M, Gallardo M. DAT imaging in drug-induced and psychogenic parkinsonism. Mov Disord 2003;18(Suppl 7):S28-33. (Pubitemid 37336925)
32. Thanvi B, Lo N, Robinson T. Vascular parkinsonism-an important cause of parkinsonism in older people. Age Ageing 2005;34:114-119 (Pubitemid 40331090)
33. Magnus RV. A comparison of biperiden hydrochloride (Akineton) and benzhexol (Artane) in the treatment of drug-induced parkinsonism. J Int Med Res 1980;8:343-346 (Pubitemid 10018732)
34. Fann WE, Lake CR. Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry 1976;133:940-943
35. Thanvi BR, Lo TC, Harsh DP. Psychosis in Parkinson's disease. Postgrad Med J 2005;81:644-646 (Pubitemid 41498470)
36. Nguyen N, Pradel V, Micallef J, et al. Drug-induced Parkinson syndromes. Therapie 2004;59:105-112
37. Lee PH, Kim JS, Shin DH, et al. Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry 2006;77:372-374 (Pubitemid 43295162)
38. Lee PH, Yeo SH, Yong SW, et al. Odour identification test and its relation to cardiac 123I-metaiodobenzylguanidine in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry 2007;78:1250-1252 (Pubitemid 350057291)
39. Krüger S, Haehner A, Thiem C, et al. Neuroleptic-induced parkinsonism is associated with olfactory dysfunction. J Neurol 2008;255:1574-1579
40. Kim JH, Kim SY, Byun HJ. Subjective cognitive dysfunction associated with drug-induced parkinsonism in schizophrenia. Parkinsonism Relat Disord 2008;14:239-242
41. Kim JH, Byun HJ. Non-motor cognitive-perceptual dysfunction associated with drug-induced parkinsonism. Hum Psychopharmacol 2009;24:129-133